Results 3.1. Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work. Many mutations in cancer are of unknown functional significance. Focusing on original research, reviews and . Nature Reviews Cancer. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. Precision medicine approaches are ideally suited for rare tumors where comprehensive characterization may have diagnostic, prognostic, and therapeutic value. Nature Cancer: 23.177: 23.190: 5.100: 0.00816: 10.883: . Follow us on @ScimagoJRScimago Lab, Copyright 2007-2022. Citescore: 6.6. There are also other factors such as H-Index, Self-Citation Ratio, SJR, SNIP, etc. These studies should target dynamic changes in tumor biologic abnormalities, eliminating minimal residual disease, and eradicating significant subclones that confer resistance to treatment. Technological, methodological, and analytical advances continue to improve the resolution of our view into the cancer genome, even as we discover ways to carry out analyses at greater distances from the primar Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. The Dalian Institute of Chemical Physics (DICP). journal self-citations removed) received by a journal's published documents during the three previous years. Thank you for visiting nature.com. Adoptive cell therapy (ACT) is an innovative personalized treatment approach that enhances a patients immune system leading to specific tumor cell killing. Chabon JJ, Simmons AD, Lovejoy AF, et al. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience, Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study, Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial, High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Said R, Guibert N, Oxnard GR, Tsimberidou AM. three and four years have been cited in the current year. According to SCImago Journal Rank (SJR), this journal is ranked 0.219. Your privacy choices/Manage cookies we use in the preference centre. 72,993. Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers. scientist or scholar. About this Journal. Precision Cancer Medicine is published by AME Publishing Company, The Official Publication of Fudan University Shanghai Cancer Center. Submit Guidelines. Due to high clinical benefit rates, immunotherapeutic regimens have been approved by the FDA for the treatment of patients with advanced MSI-H colorectal cancer7173 or MSI-H tumors, irrespective of the organ of origin.74 Finally, defects in DNA proofreading proteins polymerase (POLD1) and polymerase (POLE) lead to increased TMB and are associated with response to immunotherapy.7577 For instance, of 4 patients with nonsmall cell lung cancer with deleterious mutations in POLD1 and POLE (whole-exome sequencing, [WES]), 3 patients with the highest TMB responded to pembrolizumab.75 Defects in other DNA repair systems might also be associated with response to immunotherapy. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. ctDNA, personalized, precision, molecular profile, matched therapy, genomic landscape, {"type":"clinical-trial","attrs":{"text":"NCT01042379","term_id":"NCT01042379"}}, {"type":"clinical-trial","attrs":{"text":"NCT01723969","term_id":"NCT01723969"}}, {"type":"clinical-trial","attrs":{"text":"NCT01827384","term_id":"NCT01827384"}}, {"type":"clinical-trial","attrs":{"text":"NCT02194738","term_id":"NCT02194738"}}, {"type":"clinical-trial","attrs":{"text":"NCT02154490","term_id":"NCT02154490"}}, {"type":"clinical-trial","attrs":{"text":"NCT02785913","term_id":"NCT02785913"}}, {"type":"clinical-trial","attrs":{"text":"NCT02965378","term_id":"NCT02965378"}}, {"type":"clinical-trial","attrs":{"text":"NCT02785939","term_id":"NCT02785939"}}, {"type":"clinical-trial","attrs":{"text":"NCT02785952","term_id":"NCT02785952"}}, {"type":"clinical-trial","attrs":{"text":"NCT02926638","term_id":"NCT02926638"}}, {"type":"clinical-trial","attrs":{"text":"NCT02766335","term_id":"NCT02766335"}}, {"type":"clinical-trial","attrs":{"text":"NCT02102165","term_id":"NCT02102165"}}, {"type":"clinical-trial","attrs":{"text":"NCT02187783","term_id":"NCT02187783"}}, {"type":"clinical-trial","attrs":{"text":"NCT02186821","term_id":"NCT02186821"}}, {"type":"clinical-trial","attrs":{"text":"NCT02091141","term_id":"NCT02091141"}}, {"type":"clinical-trial","attrs":{"text":"NCT02152254","term_id":"NCT02152254"}}, {"type":"clinical-trial","attrs":{"text":"NCT02213289","term_id":"NCT02213289"}}, {"type":"clinical-trial","attrs":{"text":"NCT02465060","term_id":"NCT02465060"}}, {"type":"clinical-trial","attrs":{"text":"NCT02534675","term_id":"NCT02534675"}}, {"type":"clinical-trial","attrs":{"text":"NCT02834013","term_id":"NCT02834013"}}, {"type":"clinical-trial","attrs":{"text":"NCT02693535","term_id":"NCT02693535"}}, {"type":"clinical-trial","attrs":{"text":"NCT02925234","term_id":"NCT02925234"}}, {"type":"clinical-trial","attrs":{"text":"NCT03155620","term_id":"NCT03155620"}}, {"type":"clinical-trial","attrs":{"text":"NCT03743428","term_id":"NCT03743428"}}, {"type":"clinical-trial","attrs":{"text":"NCT03645928","term_id":"NCT03645928"}}, {"type":"clinical-trial","attrs":{"text":"NCT03935893","term_id":"NCT03935893"}}, {"type":"clinical-trial","attrs":{"text":"NCT03108495","term_id":"NCT03108495"}}, {"type":"clinical-trial","attrs":{"text":"NCT03083873","term_id":"NCT03083873"}}, {"type":"clinical-trial","attrs":{"text":"NCT03056339","term_id":"NCT03056339"}}, {"type":"clinical-trial","attrs":{"text":"NCT00995137","term_id":"NCT00995137"}}, {"type":"clinical-trial","attrs":{"text":"NCT03656705","term_id":"NCT03656705"}}, {"type":"clinical-trial","attrs":{"text":"NCT03383978","term_id":"NCT03383978"}}. All types of documents are considered, including citable and non citable documents. 2022 www.resurchify.com All Rights Reserved. impact score may rise in 2022 as well. Standard methods use statistically significant recurrence of mutations in tumor samples as an indicator of functional impact. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists, Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists, Genomic Profiling Tests Cleared by FDA. useof impact factors of science journals easier. International Scientific Journal & Country Ranking. Cristofanilli M, Budd GT, Ellis MJ, et al. Specific guidelines of this series could be found in the Author Instructions. Recent developments in molecular biology and information technology make P. Gabrielle Bertier, Jian Carrot-Zhang, Vassilis Ragoussis and Yann Joly. Targeted Oncology | Home - Springer CiteScore. ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer. The latest impact factor of JCO Precision Oncology and all the other SCI journals was released on 30th June 2022 by Clarivate. received by a journal and the importance or prestige of the journals where The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Arlene S. Bierman, Bridget T. Burke, Leeann N. Comfort, Maya Gerstein, Nora M. Mueller, Craig A. Umscheid. Latest issue. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. Molecularly targeted agents aim to Homologous recombination (HR) is the primary pathway for repairing double-strand DNA breaks implicating in the development of cancer. Transcriptomic analysis is performed using high-throughput technologies, including microarrays and RNA sequencing and it is a potentially valuable tool, particularly when there is discrepancy between genomic alterations and gene expression. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from Increase pattern of the annual publication. The mix of unsolicited and invited submissions. We are seeking for highly motivated postdoctoral fellows to join in Dr. Thanh Hoang?s lab in the University of Michigan. A low frequency of somatic mutations but Advances in genetic analysis have revealed new complexities in the interpretation of genetic variants. Pilot study using molecular profiling of patients tumors to find potential targets and select treatments for their refractory cancers. Validation of database information can be performed by comparing outcomes of clinical trials that led to approval with those in the database; if outcomes are similar, real-world data can then be used to rapidly predict new applications for medicines. The majority of these trials2,3,12,24 have shown improvement in clinical outcomes when treatments are matched to drugs compared to when they are not. statement and Research efforts to discover effective combination treatments have f To truly achieve personalized medicine in oncology, it is critical to catalog and curate cancer sequence variants for their clinical relevance. Worst BC, van Tilburg CM, Balasubramanian GP, et al. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors, CTCs 2020: Great Expectations or Unreasonable Dreams, Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Approximately 35% of patients with cancer are enrolled on clinical trials and accrual is limited by overly restrictive eligibility criteria and limited access to drugs.114 ASCO, the Friends of Cancer Research, and the FDA recommended to broaden eligibility criteria to allow more patients to participate in clinical trials and gain benefit from novel investigational therapies;115 and consequently participants will be representative of the actual patient population, increasing generalizability of the results. Home - Precision Cancer Medicine - AME Publishing Company The complexity is amplified by the dynamic, Darwinian evolutionary character of cancer cells, which undergo sequential searches for mechanisms to escape environmental constraints. This major problem in oncology is generally attributed to the lack of specific predictive biomarkers, yet a global measure of cancer c By using this website, you agree to our Forum. Traditionally, oncology trials are drug-centered, aiming to identify common attributes among patients (e.g., their tumor type or, more recently, a shared genomic abnormality) and fit them into a trial with a specific drug regimen. Herein, we review the rapid evolution of precision medicine in oncology and, in particular, the challenge and opportunity that genomic science has revealed vis--vis the need for N-of-1 treatments. The first example of molecular-based medicine for cancer patients was the use of endocrine therapy in luminal breast cancer . Show abstract. First, the rate of matching patients to drugs in these trials ranges from 5% to 49% and is mostly in the 15% to 20% range. Proteomic analysis using immunohistochemical and other assays of tumors from patients with refractory metastatic cancer led to the identification of molecular targets that could guide therapeutic decisions and was associated with longer PFS compared to the patients PFS with their prior therapy (using patients as their own controls).1 Proteomic assays are used in clinical practice to identify prognostic or predictive biomarkers for targeted treatments (hormone receptor expression, HER2 overexpression, ALK expression). Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Adoptive cell transfer as personalized immunotherapy for human cancer, Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. . This journal has an h-index of 3. Journal Matcher. This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. Journal Metrics: Cancer Medicine. Despite the current practical limitations, protein and transcript assays may provide essential information when integrated with genomics.13 Recently, panels that incorporate immune signatures, based on DNA, RNA, and/or proteins, have also gained clinical significance.35, Given the advances in NGS technologies and the large number of laboratories in the US that perform Clinical Laboratory Improvement Amendments (CLIA)-certified NGS, optimization of the accuracy, reproducibility, and standardization of sequencing methods; variant annotation; and data interpretation is critical. Journal Self-citation is defined as the number of citation from a journal citing article to articles published by the same journal. Journal Rankings on Oncology - Scimago Journal & Country Rank Symposiums OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC, FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors, Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Guest editors: Michael Berger and Eliezer Van Allen. Cambridge Prisms: Precision Medicine | Cambridge Core It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Currently, genomics is the main factor influencing precision medicine in oncology. Two drug approvals by the FDA were based, at least in part, on such data: pembrolizumab for any solid tumor with a mismatch repair gene defect (https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm) and palbociclib for male breast cancer (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635276.htm). The rapidly expanding body of knowledge about the roles of genomics and the immune system in cancer has enabled the development of therapies targeted to specific molecular alterations or other biologic characteristics, such as those implicated in immune suppression.